No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Chart series for revenue are being prepared.
No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Chart series for revenue are being prepared.
The latest delayed quote for Vogenx Inc. (VOGX) stock was $16.39 as of Oct 6, 2026, 4:00 PM EDT, down 4.43% from the previous close.
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Biotechnology · Raleigh, NC
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.07
vs Estimate
$-0.04
Revenue
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1VOGX | $227.91M | $16.39 | -4.43% | N/A | N/A | N/A | N/A |
| 2BDSX | $227.60M | $27.96 | -3.79% | +273.09% | -28.49% | N/A | vs VOGX |
| 3NAUT | $225.24M | $1.77 | -5.35% | +111.12% | -20.56% | N/A | vs VOGX |
| 4MGNX | $231.37M | $3.64 | -3.45% | +111.04% | -28.42% | -18.75% | vs VOGX |
| 5GLSI | $231.77M | $15.79 | -6.62% | +54.67% | -14.84% | N/A | vs VOGX |
| 6IFRX | $232.72M | $1.58 | -5.95% | +6.30% | -7.34% | N/A | vs VOGX |
N/A
vs Estimate
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$55.00
+235.6% upside
Low
$55.00
Current
$16.39
High
$55.00